Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics

2022-06-28

The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.¹ Many cancers can be cured if detected early and treated effectively.¹
The Roche Digital Pathology solution helps empower the digital transformation of pathology and enable better, more personalised healthcare.

Basel, 28 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the CE launch of the next-generation VENTANA DP 600 slide scanner (CE-IVD marked). This high-capacity slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab.

“The VENTANA DP 600 slide scanner is an important tool in the advancement of personalised healthcare. In combination with our innovative AI image analysis algorithms, this solution can help ensure that each patient receives the most effective treatment plan possible,” said Thomas Schinecker, CEO of Roche Diagnostics. “It also creates opportunities for better collaboration and remote diagnosis, which can be lifesaving in areas with limited access to pathologists.”

The VENTANA DP 600 slide scanner is an important addition to the Roche Digital Pathology portfolio, which provides innovative, high-quality digital solutions that automate tissue diagnostics and empower pathologists to provide faster and more comprehensive diagnostic results to healthcare providers and their patients.

Digital Pathology refers to the digitalisation of the traditional pathology workflow starting from slide scanning to visualisation to analysis. Digital Pathology is transforming traditional histopathology by improving efficiency, depth of analysis, and opportunity for collaboration in pathology workflows.

For example, once the slide scanner captures and converts stained tissue on glass slides to digital images, these images can be managed, shared, and analysed by pathologists and can help determine a cancer patient’s treatment.

This new 240-slide scanner, which builds on the success of the 6-slide VENTANA DP 200 scanner, will help anatomic pathology laboratories accelerate the digitalisation of their pathology workflow. Both scanners feature the same innovative optics and dynamic focus technology for high-resolution, high-quality colour images that accurately reproduce the image quality that pathologists see under microscopes.

About Roche Digital Pathology
Built by pathologists, for pathologists, the end-to-end Roche Digital Pathology solution focuses on maximising the pathologists' unique training, skills, and vision. The Roche Digital Pathology solution is an integrated solution that combines innovative slide scanners, patient-centric pathology workflow software and image analysis algorithms, working in integrated harmony with the full Roche tissue diagnostics portfolio.

The newest addition to the Roche Digital Pathology portfolio is the 240-slide, high-capacity brightfield VENTANA DP 600 slide scanner that offers workflow flexibility to suit a variety of anatomical pathology labs.

VENTANA slide scanners use tray-based systems engineered with minimal moving parts. The slides move through the system on the tray without interference by a robotic mechanism, allowing for a high quality scan even if the slides are wet, frozen, or if cover slips are slightly off centre. The tray based system eliminates slide-handling errors such as breakage and loss of slides.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.r oche.com.

All trademarks used or mentioned in this release are protected by law.The VENTANA DP 600 slide scanner is available as Research Use Only (RUO) in the United States, not for use in diagnostic procedures. Refer to the product-specific labelling for the regulatory status of scanners and/or algorithms.

References
[1] WHO Cancer Facts, https://www.who.int/news-room/fact-sheets/detail/cancer

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD Phone: +41 61 687 41 47	Karsten Kleine Phone: +41 61 682 28 31
Nina Mählitz Phone: +41 79 327 54 74	Nathalie Meetz Phone: +41 79 771 05 25
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67	Sileia Urech Phone: +41 79 935 81 48

Roche Investor Relations

Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com